Mark Panzer, NACDS chairman of the Board and senior vice president, pharmacy, health and wellness, Albertsons Companies, delivered remarks during Sunday's Business Program at the 2019 NACDS Annual Meeting.
A poll of registered voters, conducted by Morning Consult and commissioned by NACDS, includes findings that can help make the case for direct and indirect remuneration (DIR) fee relief, and for broader reimbursement issues.
NACDS’ Congressional statement keys on lowering patients’ costs at pharmacy counter, reducing overall healthcare costs, and fostering pharmacy viability by preventing below-cost reimbursement.
"On social media, we saw a photo of NACDS Board of Directors member Richard Ashworth, president, operations, Walgreen Co., at a white board in the office of U.S. Sen. Bill Cassidy (R-LA), literally drawing out an example for the Senator that demonstrates the need for fair pharmacy reimbursement, for transparency in the prescription drug supply chain, and for appropriate pharmacy metrics that should be tethered to DIR fee reform."
Morning Consult today published an opinion piece by the NACDS entitled “DIR Fee Reform: Lining Up Another Win for Patients on Drug Costs.”
Inside–the–Beltway publications will send a strong message next week: Pharmacy stands as a trusted source of cost–reducing policy strategies, and DIR fee reform tops the agenda.
NACDS and NCPA held a briefing this week on DIR fee reform for the Congressional Doctors Caucus. The Caucus is comprised of 16 medical providers in Congress who use their medical expertise to develop patient-centered healthcare policy.
Rep. Cathy McMorris Rodgers (R-WA), a consistently pro-pharmacy advocate, led a letter to Health and Human Services Secretary Alex Azar urging support for DIR fee reform.
NACDS today submitted a statement to the U.S. House of Representatives Committee on Ways and Means for the hearing titled “The Cost of Rising Prescription Drug Prices.”
NACDS and the National Community Pharmacists Association (NCPA) today lauded 24 patient and consumer groups for advocating for pharmacy direct and indirect remuneration (DIR) fee reform.
